GLTO
Damora Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.58
−3.36%Sep 28, 2026, 11:14 UTC
Jennifer Jarrett bought 12,500 shares of Damora Therapeutics (DMRA.US) for $252,875 on September 25, 2026, per a Form 4 filed with the SEC.
Source:Aug 5, 2026, 12:00 UTC
Damora Therapeutics initiated the global Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis, following health authority approval.
Source:Jul 17, 2026, 12:00 UTC
Damora Therapeutics completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026.
Source: